v3.25.2
Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]        
Revenue $ 239,240 $ 415,484 $ 905,895 $ 509,339
Cost of sales 15,325 46,242 29,439 105,451
Research and development expenses: 79,233 106,946 168,170 199,625
Net income 106,508 162,381 625,154 14,831
Reportable Segment        
Segment Reporting Information [Line Items]        
Revenue 239,240 415,484 905,895 509,339
Cost of sales 15,325 46,242 29,439 105,451
Selling, general, and administrative expense 43,612 101,298 91,702 188,096
Other segment income (expense) 5,438 1,383 8,570 (1,336)
Net income 106,508 162,381 625,154 14,831
Reportable Segment | Employee and benefit expenses        
Segment Reporting Information [Line Items]        
Research and development expenses: 36,149 42,415 76,060 85,873
Reportable Segment | Facility and other research and development expenses        
Segment Reporting Information [Line Items]        
Research and development expenses: 22,048 23,319 42,668 47,054
Reportable Segment | Direct coronavirus vaccines        
Segment Reporting Information [Line Items]        
Research and development expenses: 20,194 40,812 46,722 65,962
Reportable Segment | Direct other vaccine development programs        
Segment Reporting Information [Line Items]        
Research and development expenses: $ 842 $ 400 $ 2,720 $ 736